Last reviewed · How we verify
Infiltration - EXPAREL
EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged infiltration anesthesia and post-operative pain relief.
EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged infiltration anesthesia and post-operative pain relief. Used for Infiltration anesthesia for surgical procedures, Post-operative analgesia following surgery.
At a glance
| Generic name | Infiltration - EXPAREL |
|---|---|
| Also known as | bupivacaine liposomal injectable suspension |
| Sponsor | Pacira Pharmaceuticals, Inc |
| Drug class | Long-acting local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
EXPAREL contains liposomal bupivacaine, which encapsulates bupivacaine in lipid vesicles to enable slow, sustained release of the anesthetic agent over an extended period. By blocking voltage-gated sodium channels in nerve cell membranes, it prevents action potential propagation and transmission of pain signals, providing anesthesia that can last up to 72 hours when infiltrated into surgical sites.
Approved indications
- Infiltration anesthesia for surgical procedures
- Post-operative analgesia following surgery
Common side effects
- Injection site pain or reaction
- Nausea
- Vomiting
- Headache
- Dizziness
Key clinical trials
- Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population (PHASE2)
- Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery (PHASE4)
- A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction (PHASE4)
- Pectoralis and Serratus Muscle Blocks (PHASE4)
- Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine (NA)
- A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients (PHASE4)
- Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair (PHASE4)
- Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infiltration - EXPAREL CI brief — competitive landscape report
- Infiltration - EXPAREL updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI